EDGE / EA Series Trust - MRBL Enhanced Equity ETF - SEC-Einreichungen, Jahresbericht, Proxy Statement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2026 PDS BIOTECHNOLOGY CORP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2026 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

SECURITIES PURCHASE AGREEMENT

Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of April 30, 2026, is between PDS BIOTECHNOLOGY CORPORATION, a company incorporated under the laws of the State of Delaware (the “Company”), and YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”). WITNESSETH WHEREAS, the parties desire that, upon the te

GUARANTY AGREEMENT

Exhibit 10.3 Execution Version GUARANTY AGREEMENT This Guaranty (as amended, amended and restated, supplemented or otherwise modified from time to time, this “Guaranty”) is made as of May , 2026, by PDS OPERATING CORPORATION, a Delaware corporation, and any subsequent party that may join in this Guaranty as a guarantor, the “Guarantors”) in favor of YA II PN, LTD. (“YA II” or the “Creditor”), with

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37568 PDS Biotechno

PDS BIOTECHNOLOGY CORPORATION Promissory Note

Exhibit 4.1 Execution Version NEITHER THIS NOTE (AS DEFINED BELOW) NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THIS NOTE AND THOSE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN ACQUIRED SOLELY FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARD RESALE AND HAVE BEEN SOLD

REGISTRATION RIGHTS AGREEMENT

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) dated as of [], 2026 is made by and between YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”), and PDSB BIOTECHNOLOGY CORPORATION, a company incorporated under the laws of the State of Delaware (the “Company”). The Investor and the Company may be referred to herein individually a

PDS BIOTECHNOLOGY CORPORATION Warrant To Purchase Common Shares

Exhibit 4.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T

PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update Investor Webcast Scheduled for 8:00 am ET

Exhibit 99.1 PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update Investor Webcast Scheduled for 8:00 am ET PRINCETON, N.J., May 13, 2026 - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2026 PDS BIOTECHNOLOGY CORP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2026 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2026 PDS BIOTECHNOLOGY CO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2026 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37568 PDS Biotec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2026 PDS BIOTECHNOLOGY CO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2026 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Precision Designed Science for Cancer Patients NASDAQ: PDSB April 2026 months 12-18 months for current standard of care1 Keytrud (pembrolizumab) benchmark in First-line (1L) treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (1L

Exhibit 99.1 Precision Designed Science for Cancer Patients NASDAQ: PDSB April 2026 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Com

PDS BIOTECHNOLOGY CORPORATION 303A College Road East Princeton, NJ 08540

PDS BIOTECHNOLOGY CORPORATION 303A College Road East Princeton, NJ 08540 April 24, 2026 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.

As filed with the Securities and Exchange Commission on April 24, 2026

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 24, 2026 Registration No.

CALCULATION OF FILING FEE TABLE Form S-3 (Form Type) PDS Biotechnology Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-3 (Form Type) PDS Biotechnology Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount to be registered Proposed maximum offering price per unit Maximum Aggregate Offering Price Fee Rate Amount of registration fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, par value $0.

PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial 78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR

Exhibit 99.1 PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial 78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year survival rate of >80%; Parallel trial without PDS01ADC resulted in 2-year survival rate of ~35% Trials performed in unresectable m

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2026 PDS BIOTECHNOLOGY CO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2026 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2026 PDS BIOTECHNOLOGY CO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2026 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37568 PDS Biotechnology Corporation

PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement Filed Phase 3 Amendment Incorporates PFS as Interim Primary Endpoint Expected to Shorten Trial Duration and Reduce C

Exhibit 99.1 PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement Filed Phase 3 Amendment Incorporates PFS as Interim Primary Endpoint Expected to Shorten Trial Duration and Reduce Costs Conference Call and Webcast Today at 8:00 am Eastern Time PRINCETON, N.J., March 30, 2026 - PDS Biotechnology Corporation (Nasdaq: P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2026 PDS BIOTECHNOLOGY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2026 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Precision Designed Science for Cancer Patients NASDAQ: PDSB February 2026 A Promising Approach to Treating HPV16-Positive Head and Neck Cancers Targeted immunotherapy with compelling clinical results and regulatory path to accelerated approval CLINIC

Exhibit 99.1 Precision Designed Science for Cancer Patients NASDAQ: PDSB February 2026 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2026 PDS BIOTECHNOLOGY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2026 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2026 PDS BIOTECHNOLOGY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2026 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval Enables Potential Shorter Time to Accelerated

Exhibit 99.1 PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval Enables Potential Shorter Time to Accelerated Approval of PDS0101 in HPV16-positive Head and Neck Cancer PRINCETON, N.J., February 20, 2026 - PDS Biotechnology Corporation (Nasdaq: P

PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI NCI-Led Study Shows Median PFS of 9.6 Months Results

Exhibit 99.1 PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI NCI-Led Study Shows Median PFS of 9.6 Months Results Presented at AACR Special Conference on Innovations in Prostate Cancer PRINCETON, N.J., January 28, 2026 - PDS Biotechnology Corporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2026 PDS BIOTECHNOLOGY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2026 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101 Patent Enhances IP Estate for Lead Asset; Combined with Anticipated Biologics Exclusivity, Market Protections Extend Over 20 Years

Exhibit 99.1 PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101 Patent Enhances IP Estate for Lead Asset; Combined with Anticipated Biologics Exclusivity, Market Protections Extend Over 20 Years PRINCETON, N.J., January 22, 2026 - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2026 PDS BIOTECHNOLOGY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2026 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint

Exhibit 99.1 PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint PDS Biotech Submits Amended Protocol for Phase 3 VERSATILE-003 Trial Constructive Type C Meeting Provides Potential Pathway to Accelerated Approval of PDS0101 PRINCETON, N.J., January 9, 2026 - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage imm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2026 PDS BIOTECHNOLOGY C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2026 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

As filed with the Securities and Exchange Commission on December 12, 2025

As filed with the Securities and Exchange Commission on December 12, 2025 Registration No.

Calculation of Filing Fee Tables Form S-8 (Form Type) PDS Biotechnology Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) PDS Biotechnology Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2025 PDS BIOTECHNOLOGY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan

Exhibit 99.1 PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan New Patent Grants Broad Composition Claims for PDS0101 Previously Granted Patent Protections and Anticipated Market Exclusivity Provide Protection for PDS0101 in the United States into the 2040s PRINCETON, N.J., December 9, 2025 - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a

PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)

Exhibit 99.1 PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”) Company to Discuss Proposed Amendment to Phase 3 VERSATILE-003 Trial Enabling Potential Accelerated Approval Pathway PRINCETON, N.J., December 2, 2025 - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transformin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2025 PDS BIOTECHNOLOGY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37568 PDS Biote

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2025 PDS BIOTECHNOLOGY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

Exhibit 99.1 PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update Company Announced Completion of VERSATILE-002 Phase 2 trial of PDS0101 + Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Cancer Phase 2 Results Lead Company to Seek Expedited Approval Pathway in Ongoing VERSATILE-003 Phase 3 Trial Design Conference Call and Webcast today a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2025 PDS BIOTECHNOLOGY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

[Signature Page Follows]

Exhibit 4.3 November 11, 2025 Holder of Warrants to Purchase Common Stock set forth on Exhibit A attached hereto Re: Amendment to Existing Warrants Dear Holder: Reference is hereby made to the offering on or about the date hereof (the “Offering”) by PDS Biotechnology Corporation (the “Company”) of its common stock, par value $0.00033 per share (“Common Stock”) and warrants to purchase its Common S

LOCK-UP AGREEMENT

Exhibit 10.2 LOCK-UP AGREEMENT , 2025 Re: Securities Purchase Agreement, dated as of November 11, 2025 (the “Purchase Agreement”), between PDS Biotechnology Corporation (the “Company”) and the purchasers signatory thereto (each, a “Purchaser” and, collectively, the “Purchasers”) Ladies and Gentlemen: Defined terms not otherwise defined in this letter agreement (the “Letter Agreement”) shall have t

PRE-FUNDED COMMON STOCK PURCHASE WARRANT PDS BIOTECHNOLOGY CORPORATION

Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT PDS BIOTECHNOLOGY CORPORATION Warrant Shares: Initial Exercise Date: , 2025 Issue Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time

SECURITIES PURCHASE AGREEMENT

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 11, 2025 between PDS Biotechnology Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and co

5,741,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 59,000 Shares of Common Stock Warrants to Purchase up to 5,800,000 Shares of Common Stock Up to 5,859,000 Shares of Common Stock Underlying the Warrants and Pre-Funded Warrants

TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-267041 PROSPECTUS SUPPLEMENT (To Prospectus dated September 2, 2022) 5,741,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 59,000 Shares of Common Stock Warrants to Purchase up to 5,800,000 Shares of Common Stock Up to 5,859,000 Shares of Common Stock Underlying the Warrants and Pre-Funded Warrants   We are of

COMMON STOCK PURCHASE WARRANT PDS BIOTECHNOLOGY CORPORATION

Exhibit 4.2 COMMON STOCK PURCHASE WARRANT PDS BIOTECHNOLOGY CORPORATION Warrant Shares: Initial Exercise Date: , 20261 Issue Date: , 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after , 20261

PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering $5.3 million Upfront with up to an Additional $5.8 million of Aggregate Gross Proceeds upon the Cash Exercise in Full of Warrants

Exhibit 99.1 PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering $5.3 million Upfront with up to an Additional $5.8 million of Aggregate Gross Proceeds upon the Cash Exercise in Full of Warrants PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transfo

PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

Exhibit 99.1 PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025 • Translational study shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapy • PDS01ADC reprograms natural killer (NK) cells to possess characteristics that make them more active in killing c

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2025 PDS BIOTECHNOLOGY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer Company aims to shorten time frame to make PDS0101 available to patients with HPV16-positive head and neck cancer, projected to be the most dominant typ

Exhibit 99.1 PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer Company aims to shorten time frame to make PDS0101 available to patients with HPV16-positive head and neck cancer, projected to be the most dominant type of head and neck cancer in the US by mid 2030s Proposed Amendment to Ongoing VERSATILE-003 Trial to include PFS Endpoint Based Upon Fin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2025 PDS BIOTECHNOLOGY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population First combination therapy

Exhibit 99.1 PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population First combination therapy to report 29.5 months of Median Overall Survival (mOS); Standard of care Keytruda® (pembrolizumab) alone (10.8 months) and Keytruda® + ch

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2025 PDS BIOTECHNOLOG

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

LETTER

September 4, 2025 Frank Bedu-Addo, Ph.D. President and Chief Executive Officer PDS Biotechnology Corporation 303A College Road East Princeton, NJ 08540 Re: PDS Biotechnology Corporation Registration Statement on Form S-3 Filed August 29, 2025 File No. 333-289942 Dear Frank Bedu-Addo Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer

As filed with the Securities and Exchange Commission on August 29, 2025

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 29, 2025 Registration No.

Calculation of Filing Fee Table Form S-3 (Form Type) PDS Biotechnology Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) PDS Biotechnology Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount to be registered Proposed maximum offering price per unit Maximum Aggregate Offering Price Fee Rate Amount of registration fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, par value $0.

PDS Biotechnology Corporation Dated as of [●] TABLE OF CONTENTS

Exhibit 4.3 PDS Biotechnology Corporation INDENTURE Dated as of [●] [●] Trustee TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS SECTION 1.01. Certain Terms Defined 1 SECTION 1.02. Other Definitions 5 SECTION 1.03. Rules of Construction 5 ARTICLE 2 SECURITY FORMS SECTION 2.01. Forms Generally 5 SECTION 2.02. Guarantees by Guarantor; Form of Guarantee; Release of Guarantee 5 SECTION 2.03. Form of Trust

PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with standard of care pembrolizumab or pembrolizu

Exhibit 99.1 PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with standard of care pembrolizumab or pembrolizumab + chemotherapy is 17.9 months* VERSATILE-003 Phase 3 trial in progress PRINCETON, N.J., August 25, 2025 - PDS Biotechnology Corporati

Precision Designed Science for Cancer Patients NASDAQ: PDSB August 2025 Multiple Opportunities for Value Creation Potential for Leadership in HPV16+ HNSCC Positive results in Phase 2 Trial of PDS0101 in HPV16+ 1L R/M HNSCC Median overall survival (OS

Exhibit 99.1 Precision Designed Science for Cancer Patients NASDAQ: PDSB August 2025 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Co

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2025 PDS BIOTECHNOLOGY C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update

Exhibit 99.1 PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update Multiple Abstracts Presented at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., August 13, 2025 - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunother

PDS BIOTECHNOLOGY CORPORATION RESTRICTED STOCK UNITS NOTICE UNDER THE PDS BIOTECHNOLOGY CORPORATION THIRD AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN

Exhibit 10.7 PDS BIOTECHNOLOGY CORPORATION RESTRICTED STOCK UNITS NOTICE UNDER THE PDS BIOTECHNOLOGY CORPORATION THIRD AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN Name of Grantee: This Notice evidences the award of restricted stock units (each, an “RSU,” and collectively, the “RSUs”) of PDS Biotechnology Corporation, a Delaware corporation (the “Company”), that have been granted to you pursuan

AMENDMENT AGREEMENT

Exhibit 10.2 AMENDMENT AGREEMENT This Amendment Agreement (this “Agreement”) is entered into as of May 20, 2025, by and among JGB Capital, L.P., JGB Partners, L.P., JGB Capital Offshore Ltd. and Alto Opportunity Master Fund SPC – Segregated Master Portfolio B (collectively, the “Buyers”), PDS Biotechnology Corporation, a Delaware corporation (the “Company”) and JGB Collateral LLC, as Collateral Ag

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 PDS BIOTECHNOLOGY C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37568 PDS Biotechnol

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2025 PDS BIOTECHNOLOGY COR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results Metastatic Colorectal Cancer Cohort in NCI-Led Multi-Cohort Study Demonstrates Promising R

Exhibit 99.1 PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results Metastatic Colorectal Cancer Cohort in NCI-Led Multi-Cohort Study Demonstrates Promising Response Rate, Triggering Enrollment Expansion Under Simon Two-Stage Design PRINCETON, N.J., July 10, 2025 - PDS Biotechnology Corporation

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Addressing the Growing Incidence of HPV16-Related Cancers NASDAQ: PDSB June 2025 Precision Designed Science For Immunotherapy Targeting HPV16-positive Head and Neck Cancer with Versamune® HPV Potential for Market Leadership Position Addressing Critic

Exhibit 99.1 Addressing the Growing Incidence of HPV16-Related Cancers NASDAQ: PDSB June 2025 Precision Designed Science For Immunotherapy Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amen

AMENDMENT TO THE THIRD AMENDED AND RESTATED PDS BIOTECHNOLOGY CORPORATION 2014 EQUITY INVENTIVE PLAN

Exhibit 10.1 AMENDMENT TO THE THIRD AMENDED AND RESTATED PDS BIOTECHNOLOGY CORPORATION 2014 EQUITY INVENTIVE PLAN WHEREAS, PDS Biotechnology Corporation, Inc. (the “Company”) maintains the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the “Plan”); and WHEREAS, Section 9.1 of the Plan provides that the Plan may be amended from time to time; and WHEREAS, the Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 11, 2025 Date of Report (Date of earliest event reported) PDS Biotechnology Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 11, 2025 Date of Report (Date of earliest event reported) PDS Biotechnology Corporation (Exact name of registrant as specified in its charter) Delaware 001-37568 26-4231384 (State or other jurisdiction of incorporation) (Commiss

PDS BIOTECHNOLOGY CORPORATION 303A College Road East Princeton, NJ 08540

PDS BIOTECHNOLOGY CORPORATION 303A College Road East Princeton, NJ 08540 June 6, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 PDS BIOTECHNOLOGY CORP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Median overall survival data in

Exhibit 99.1 PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Median overall survival data in first-line recurrent/metastatic (1L r/m) HNSCC remains durable at 30.0 months with additional follow-up of ~4.5 months beyond the initial

LETTER

May 30, 2025 Frank Bedu-Addo President and Chief Executive Officer PDS Biotechnology Corporation 303A College Road East Princeton, NJ 08540 Re: PDS Biotechnology Corporation Registration Statement on Form S-3 Filed May 27, 2025 File No.

As filed with the Securities and Exchange Commission on May 27, 2025

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 27, 2025 Registration No.

Calculation of Filing Fee Tables FORM S-3 (Form Type) PDS Biotechnology Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities*

Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) PDS Biotechnology Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities* Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit(1) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(1) Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, $0.

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Phase 2: Versamune® HPV with pembrolizuma

Exhibit 99.1 PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Phase 2: Versamune® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC - Median overall survival for CPS ≥20 is 39.3 months - Median overall survival for CPS ≥1 i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 2)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025 PDS BIOTECHNOLOGY CORP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 PDS BIOTECHNOLOGY CORP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update

Exhibit 99.1 PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update VERSATILE-003 Phase 3 Site Initiations Underway Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., May 14, 2025 - PDS Biotechnology Corporatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37568 PDS Biotechno

PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting Infectimune® studies funded by and performed by investigators at the National Institute of Allergy and Infectious Diseases

Exhibit 99.1 PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting Infectimune® studies funded by and performed by investigators at the National Institute of Allergy and Infectious Diseases (NIAID)’s Center for Influenza Vaccine Research for High-Risk Populations (CIVR-HRP) PRINCETON, N.J., May 8, 2025 - PDS Biotechnology Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 PDS BIOTECHNOLOGY CORPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

COMMON STOCK PURCHASE WARRANT PDS BIOTECHNOLOGY CORPORATION

Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

SECURITIES PURCHASE AGREEMENT

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 30, 2025, between PDS Biotechnology Corporation, a Delaware corporation (the “Company”), each buyer identified on the signature pages hereto (each, including its successors and assigns, a “Buyer” and collectively, the “Buyers”), and JGB Collateral LLC, a Delaware limited liability

SUBSIDIARY GUARANTEE

Exhibit 10.4 SUBSIDIARY GUARANTEE SUBSIDIARY GUARANTEE, dated as of April 30, 2025 (this “Guaranty”), and made by each of the signatories hereto (together with any other entity that may become a party hereto as provided herein, the “Guarantors”), in favor of JGB Collateral LLC, a Delaware limited liability company (the “Collateral Agent”), on behalf of holders those Senior Secured Convertible Debe

REGISTRATION RIGHTS AGREEMENT

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of April 30, 2025, between PDS Biotechnology Corporation, a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities P

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

SENIOR SECURED CONVERTIBLE DEBENTURE DUE [__], 2028

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

SECURITY AGREEMENT

Exhibit 10.3 SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of April 30, 2025 (this “Agreement”), is made by PDS Biotechnology Corporation, a Delaware corporation (the “Company”), and the Subsidiaries of the Company party hereto from time to time (such subsidiaries, the “Guarantors” and together with the Company, the “Debtors”) in favor of the JGB Collateral LLC, a Delaware limited liability

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:          ☐     Preliminary Proxy Statement  ☐     Confidential, for Use of the Commission Only (as

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒       Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy

ARS

PDS Biotechnology PDS BIOTECHNOLOGY CORPORATION  2Ͷ Annual Report 81,7('67$7(6 6(&85,7,(6$1'(;&+$1*(&200,66,21 :DVKLQJWRQ'&  )250.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

Exhibit 99.1 PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update Initiated VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., March 27, 2025 - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stag

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37568 PDS Biotechnology Corporation

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institu

Exhibit 99.1 PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute Second Versamune® platform candidate targets MUC1-positive solid tumors U.S. Patent #12,201,685 covering methods of using combinations

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer First-ever HPV16-positive head and neck cancer Phase 3 clinical trial

Exhibit 99.1 PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer First-ever HPV16-positive head and neck cancer Phase 3 clinical trial PRINCETON, N.J., March 7, 2025 - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system

6,396,787 Shares of Common Stock Pre-Funded Warrants to Purchase up to 933,334 Shares of Common Stock Warrants to Purchase up to 7,330,121 Shares of Common Stock

TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-267041 PROSPECTUS SUPPLEMENT (To Prospectus dated September 2, 2022) 6,396,787 Shares of Common Stock Pre-Funded Warrants to Purchase up to 933,334 Shares of Common Stock Warrants to Purchase up to 7,330,121 Shares of Common Stock   We are offering on a “best efforts” basis 6,396,787 shares (the “Shares”) of our common stock,

COMMON STOCK PURCHASE WARRANT PDS BIOTECHNOLOGY CORPORATION

Exhibit 4.2 COMMON STOCK PURCHASE WARRANT PDS BIOTECHNOLOGY CORPORATION Warrant Shares: Issue Date: [ ], 2025 Initial Exercise Date: [ ], 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [th

PLACEMENT AGENCY AGREEMENT

Exhibit 10.2 PLACEMENT AGENCY AGREEMENT February 26, 2025 PDS Biotechnology Corporation 303A College Road East Princeton, NJ 08540 Attn: Chief Executive Officer Dear Dr. Bedu-Addo: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and PDS Biotechnology Corporation, a Delaware corporation (the “Company”), that the Placement Agent

PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules $11 Million Upfront with up to an Additional $11 Million of Aggregate Gross Proceeds Upon the Cash Exercise in Full of the Warrants

Exhibit 99.1 PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules $11 Million Upfront with up to an Additional $11 Million of Aggregate Gross Proceeds Upon the Cash Exercise in Full of the Warrants PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immuno

PRE-FUNDED COMMON STOCK PURCHASE WARRANT PDS BIOTECHNOLOGY CORPORATION

Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT PDS BIOTECHNOLOGY CORPORATION Warrant Shares: Issue Date: [ ], 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 PDS BIOTECHNOLOGY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

SECURITIES PURCHASE AGREEMENT

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 26, 2025 between PDS Biotechnology Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and co

PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology Median Overall Survival (mOS) of 42.4 months in immune checkpoint inhibito

Exhibit 99.1 PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology Median Overall Survival (mOS) of 42.4 months in immune checkpoint inhibitor naïve patients; Historical published result is 7-12 months Continued survival in the cohort of HPV16-positive immune checkpoint inhibit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 PDS BIOTECHNOLOGY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

Exhibit 99.1 PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research Data confirms Versamune® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025 Versamune® HPV + CRT was associated with greater and earlier clearance of blood-

Transforming How the Immune System Targets and Fights Cancer to Promote Survival NASDAQ: PDSB February 2025 Precision Designed Science For Immunotherapy

Exhibit 99.2 Transforming How the Immune System Targets and Fights Cancer to Promote Survival NASDAQ: PDSB February 2025 Precision Designed Science For Immunotherapy Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 27E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Secu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Exhibit 99.1 PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma FDA-cleared amended trial design; First site initiation expected Q1 2025 PRINCETON, N.J., February 5, 2025 - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunothe

1 © 2024 PDS Biotechnology. All Rights Reserved. Transforming How the Immune System Targets and Fights Cancer to Promote Survival Precision Designed Science For Immunotherapy NASDAQ: PDSB November 2024 Late-Stage Head and Neck Cancer Program as Value

Exhibit 99.2 1 © 2024 PDS Biotechnology. All Rights Reserved. Transforming How the Immune System Targets and Fights Cancer to Promote Survival Precision Designed Science For Immunotherapy NASDAQ: PDSB November 2024 Forward-Looking Statements 2 This communication contains forward-looking statements (including within the meaning of Section 27E of the United States Securities Exchange Act of 1934, as

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37568 PDS Biote

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results

Exhibit 99.1 PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results Conference call and webcast today at 8:30 a.m. Eastern Time PRINCETON, N.J., November 14, 2024 - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the d

IMMUNOCERV Phase II Trial Combining the HPV-specific T Cell Immunotherapy PDS0101 with Chemoradiation for Treatment of Locally Advanced Cervical Cancer Adam J Grippin1, Kyoko Yoshida-Court1, Madison O’Hara1, Olsi Gjyshi2, Geena Mathew1, Maliah Doming

Exhibit 99.2 IMMUNOCERV Phase II Trial Combining the HPV-specific T Cell Immunotherapy PDS0101 with Chemoradiation for Treatment of Locally Advanced Cervical Cancer Adam J Grippin1, Kyoko Yoshida-Court1, Madison O’Hara1, Olsi Gjyshi2, Geena Mathew1, Maliah Domingo1, Lilie Lin1, Anuja Jhingran1, Melissa Joyner1, Tatiana Cisneros Napravnik1, Kathleen Schmeler1, Michael Hernandez1, Erica Lynn1, Aaron

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation 100% 36-month overall survival (OS) and progression-free survival (PFS) rates in patients fully

Exhibit 99.1 PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation 100% 36-month overall survival (OS) and progression-free survival (PFS) rates in patients fully treated with Versamune® HPV combined with chemoradiation (N=8) 88% (15/17) of patients had a complete metabolic response IMMUNOCERV Phase

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2024 PDS BIOTECHNOLOGY C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2024 PDS BIOTECHNOLOG

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2024 PDS BIOTECHNOLOG

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024 Median Overall Survival remains at 30 months; Objective Response Rate of 36% and Disease Control Rate of 77% 11/53 (21%) of patients experienced 90

Exhibit 99.1 PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024 Median Overall Survival remains at 30 months; Objective Response Rate of 36% and Disease Control Rate of 77% 11/53 (21%) of patients experienced 90-100% tumor shrinkage VERSATILE-003 Phase 3 clinical trial planned to begin this year PRINCETON, N.J., September 16, 2024 - PDS Biotechno

Transforming How the Immune System Targets and Fights Cancer to Promote Survival NASDAQ: PDSB September 2024 Precision Designed Science For Immunotherapy Late-Stage Head and Neck Cancer Program as Value Catalyst Potent Long-Lasting “Memory” T Cells H

Exhibit 99.1 Transforming How the Immune System Targets and Fights Cancer to Promote Survival NASDAQ: PDSB September 2024 Precision Designed Science For Immunotherapy Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 27E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Sec

PDS Biotech Provides Business Update and Reports Second Quarter 2024 Financial Results

Exhibit 99.1 PDS Biotech Provides Business Update and Reports Second Quarter 2024 Financial Results PRINCETON, N.J., August 13, 2024 - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today provided a business u

PDS BIOTECHNOLOGY CORPORATION Common Stock (par value $0.00033 per share) Amended and Restated At Market Issuance Sales Agreement

Exhibit 10.1 Execution Version PDS BIOTECHNOLOGY CORPORATION Common Stock (par value $0.00033 per share) Amended and Restated At Market Issuance Sales Agreement August 13, 2024 B. Riley Securities, Inc. 299 Park Avenue, 21st Floor New York, NY 10171 H.C. Wainwright & Co., LLC 430 Park Avenue New York, NY 10022 Ladies and Gentlemen: PDS Biotechnology Corporation, a Delaware corporation (the “Compan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37568 PDS Biotechnol

Up to $50,000,000

TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-267041 PROSPECTUS SUPPLEMENT (To Prospectus dated September 2, 2022) Up to $50,000,000   Common Stock We have entered into an amended and restated At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley Securities, Inc. and H.C. Wainwright & Co., LLC (each an “Agent” and collectively the “Agents”) relating to

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Announces Abstract Accepted for Oral Presentation at 2024 ASTRO Annual Meeting

Exhibit 99.1 PDS Biotech Announces Abstract Accepted for Oral Presentation at 2024 ASTRO Annual Meeting PRINCETON, N.J., August 8, 2024 - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that upd

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 PDS BIOTECHNOLOGY CO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024

Exhibit 99.1 PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024 PRINCETON, N.J., August 7, 2024 - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will r

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 PDS BIOTECHNOLOGY CO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Announces Abstract Accepted for Presentation at ESMO Congress 2024

Exhibit 99.1 PDS Biotech Announces Abstract Accepted for Presentation at ESMO Congress 2024 PRINCETON, N.J., August 5, 2024 - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that an abstract pre

Transforming How the Immune System Targets and Fights Cancer to Promote Survival NASDAQ: PDSB August 2024 Precision Designed Science For Immunotherapy Late-Stage Head and Neck Cancer Program as Value Catalyst Potent Long-Lasting “Memory” T Cells High

Exhibit 99.2 Transforming How the Immune System Targets and Fights Cancer to Promote Survival NASDAQ: PDSB August 2024 Precision Designed Science For Immunotherapy Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 27E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 PDS BIOTECHNOLOGY CO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern Time

Exhibit 99.1 PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern Time PRINCETON, N.J., August 1, 2024 - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on tr

CERTIFICATE OF AMENDMENT TO THE EIGHTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION PDS BIOTECHNOLOGY CORPORATION

Exhibit 10.1 CERTIFICATE OF AMENDMENT TO THE EIGHTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PDS BIOTECHNOLOGY CORPORATION PDS Biotechnology Corporation, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY THAT: FIRST: The name of the Corporation is PDS Biotechnology Corporation. SECON

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 24, 2024 Date of Report (Date of earliest event reported) PDS Biotechnology Corporation (Exact name of registrant as specified in its charter) Delaware 001-37568 26-4231384 (State or other jurisdiction of incorporation) (Commiss

Transforming How the Immune System Targets and Fights Cancer to Promote Survival NASDAQ: PDSB June 2024 Precision Designed Science For Immunotherapy Late-Stage Head and Neck Cancer Program as Value Catalyst 1. Company’s 10-K for year ended 12/31/2023

Transforming How the Immune System Targets and Fights Cancer to Promote Survival NASDAQ: PDSB June 2024 Precision Designed Science For Immunotherapy Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 27E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the "Company") and other matters.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 PDS BIOTECHNOLOGY COR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck Cancer Majority of patients continue to be followed for survival with multiple patients approaching 3 years Median Overall Survival (mOS) remains at 3

Exhibit 99.1 PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck Cancer Majority of patients continue to be followed for survival with multiple patients approaching 3 years Median Overall Survival (mOS) remains at 30 months based on the most recent data cut with approximately six months of additional follow-up PRINCETON, N.J., June 12, 2024 - PDS Bio

PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results

Exhibit 99.1 PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results Provided Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer Expanded Global Intellectual Property Surrounding Versamune® Platform PRINCETON, N.J., May 15, 2024 - PDS Biotechnology Corporati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 PDS BIOTECHNOLOGY CORP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

EXECUTIVE EMPLOYMENT AGREEMENT

Exhibit 10.3 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective May 1, 2024 (the “Effective Date”), by and between Stephan F. Toutain, MS, MBA (“Executive”) and PDS Biotechnology Corporation, a Delaware corporation (the “Company”). Each of the Company and Executive is a “Party” and, collectively, they are the “Parties.” The Company desire

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37568 PDS Biotechno

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 PDS BIOTECHNOLOGY CORPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer 30 month median overall survival (OS); median OS independent of patient CPS score ORR 34% (CPS≥1); 4

Exhibit 99.1 PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer 30 month median overall survival (OS); median OS independent of patient CPS score ORR 34% (CPS≥1); 48% (CPS≥20) Phase 3 registrational trial planned to initiate in 2024 PRINCETON, N.J., May 9, 2024 - PDS Biotechnology Corporation (Nasdaq

PDSB / PDS Biotechnology Corporation / BlackRock Inc. Passive Investment

SC 13G/A 1 us70465t1079050724.txt us70465t1079050724.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) PDS Biotechnology Corp - (Name of Issuer) Common Stock - (Title of Class of Securities) 70465T107 - (CUSIP Number) April 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate bo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 PDS BIOTECHNOLOGY CORPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Transforming How the Immune System Targets and Fights Cancer to Promote Survival © 2024 PDS Biotechnology. All Rights Reserved. NASDAQ: PDSB May 2024 Precision Designed Science For Immunotherapy Late-Stage Head and Neck Cancer Program as Value Cataly

Exhibit 99.1 Transforming How the Immune System Targets and Fights Cancer to Promote Survival © 2024 PDS Biotechnology. All Rights Reserved. NASDAQ: PDSB May 2024 Precision Designed Science For Immunotherapy Forward-Looking Statement This communication contains forward-looking statements (including within the meaning of Section 27E of the United States Securities Exchange Act of 7934, as amended,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 PDS BIOTECHNOLOGY CORPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Appoints Stephan Toutain as Chief Operating Officer

Exhibit 99.1 PDS Biotech Appoints Stephan Toutain as Chief Operating Officer Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PRINCETON, N.J., May 2, 2024 - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease va

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒       Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy

ARS

PDS Biotechnology PDS BIOTECHNOLOGY CORPORATION 2023 Annual Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rul

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☒ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule

PDS BIOTECHNOLOGY CORPORATION POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED INCENTIVE COMPENSATION (Adopted October 19, 2023)

Exhibit 97 PDS BIOTECHNOLOGY CORPORATION POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED INCENTIVE COMPENSATION (Adopted October 19, 2023) 1.

Calculation of Filing Fee Tables Form S-8 (Form Type)

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) PDS Biotechnology Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37568 PDS Biotechnology Corporation

Subsidiaries of PDS Biotechnology Corporation

Exhibit 21.1 Subsidiaries of PDS Biotechnology Corporation Name State or other Jurisdiction of Incorporation or Organization PDS Operating Corporation Delaware

EXECUTIVE EMPLOYMENT AGREEMENT

Exhibit 10.26 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective December 4, 2023 (the “Effective Date”), by and between Lars Robert Boesgaard (“Executive”) and PDS Biotechnology Corporation, a Delaware corporation (the “Company”). Each of the Company and Executive is a “Party” and, collectively, they are the “Parties.” The Company desire

EXECUTIVE EMPLOYMENT AGREEMENT

Exhibit 10.27 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective January 16, 2024 (the “Effective Date”), by and between Kirk V. Shepard, MD (“Executive”) and PDS Biotechnology Corporation, a Delaware corporation (the “Company”). Each of the Company and Executive is a “Party” and, collectively, they are the “Parties.” The Company desires

As filed with the Securities and Exchange Commission on March 28, 2024

As filed with the Securities and Exchange Commission on March 28, 2024 Registration No.

PDS Biotechnology Corporation Policy on Insider Trading

Exhibit 19 Title: Insider Trading Policy SOP Number: LEG-POL-002 Version Number: V00 Supersedes: Initial Effective Date: Next Review Due By: October 2026 PDS Biotechnology Corporation Policy on Insider Trading 1.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Announces Clinical Strategy Update and Reports

Exhibit 99.1 PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results Unique mechanism of action of the combination of PDS01ADC and Versamune® results in 3-year survival of 75% and 75% overall response rate in advanced head and neck cancer trial As a result, Company to focus late-stage clinical strategy on triple combination of PDS01ADC, PDS0101 (Versamune® HPV)

Transforming How the Immune System Targets and Fights Cancer NASDAQ: PDSB March 2024 Late-Stage Head and Neck Cancer Program as Value Catalyst Pivotal trial planned for PDS01ADC + Versamune® HPV (PDS0101) + KEYTRUDA® in head and neck cancer High-Valu

Exhibit 99.2 Transforming How the Immune System Targets and Fights Cancer NASDAQ: PDSB March 2024 Forward-Looking Statement This communication contains forward-looking statements (including within the meaning of Section 27E of the United States Securities Exchange Act of 7934, as amended, and Section 27A of the United States Securities Act of 7933, as amended) concerning PDS Biotechnology Corporat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2024 PDS BIOTECHNOLOGY CO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®

Exhibit 99.1 PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune® Preclinical research published in Vaccines demonstrates Infectimune® significantly improved quantity and quality of potent multifunctional CD4 T cells compared to vaccine adjuvants Patent for composition of matter and use of Infectimune® based influenza vaccines gr

PDSB / PDS Biotechnology Corporation / BlackRock Inc. Passive Investment

us70465t1079012924.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) PDS Biotechnology Corp - (Name of Issuer) Common Stock - (Title of Class of Securities) 70465T107 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2024 PDS BIOTECHNOLOGY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer Board-certified oncologist and hematologist brings over 30 years of medical affairs, clinical operations leadership and comme

Exhibit 99.1 PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer Board-certified oncologist and hematologist brings over 30 years of medical affairs, clinical operations leadership and commercialization experience to the Company PRINCETON, N.J., January 22, 2024 (GLOBE NEWSWIRE) - PDS Biotechnology Corporation (Nasdaq: PDSB)

PDS BIOTECHNOLOGY CORPORATION 2019 INDUCEMENT PLAN Amended on January 22, 2024 SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS

Exhibit 10.1 PDS BIOTECHNOLOGY CORPORATION 2019 INDUCEMENT PLAN Amended on January 22, 2024 SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the PDS Biotechnology Corporation 2019 Inducement Plan (the “Plan”). The purpose of the Plan is to provide non-qualified stock options to individuals not previously employees or Non-Employee Directors of PDS Biotechnology Company (t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2023 PDS BIOTECHNOLOGY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Developing Transformational Immunotherapies for Cancer NASDAQ: PDSB December 2023 PDS0101 to enter Phase 3 registrational trial in Q1 2024 to treat recurrent or metastatic, HPV16-positive head and neck squamous cell cancer (HNSCC) Fast Track Designat

Exhibit 99.1 Developing Transformational Immunotherapies for Cancer NASDAQ: PDSB December 2023 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporatio

PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer

Exhibit 99.1 PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer PRINCETON, N.J., November 28, 2023 (GLOBE NEWSWIRE) - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell activating pl

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update

Exhibit 99.1 PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update • Announced 75% of ICI-naive patients alive at 36 months in the NCI-led triple Phase 2 combination trial for advanced HPV16-positive cancer patients; published median overall survival of 7-11 months with FDA approved ICI1 • Announced 2-year overall survival rate of 74% in VERSATILE-002 Phase 2 trial

Calculation of Filing Fee Tables Form S-8 (Form Type) PDS Biotechnology Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) PDS Biotechnology Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.

As filed with the Securities and Exchange Commission on November 14, 2023

As filed with the Securities and Exchange Commission on November 14, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37568 PDS Biote

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 PDS BIOTECHNOLOGY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101 Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which shows 75% Survival of ICI Naïve Patients at 36 Months

Exhibit 99.1 PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101 Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which shows 75% Survival of ICI Naïve Patients at 36 Months • 75% of immune checkpoint inhibitor (ICI) naïve patients remain alive at 36 months; published median overall survival (OS) in similar patients is 7-11 months •

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO

Exhibit 99.1 PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO ● Combination of PDS0101 and KEYTRUDA® appears to lead to changes towards a TH1 predominant cytokine profile reported to be associated with improved killer T cell activity ● Lowered CD8 T cells in peripheral blood after treatment align with previously repo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2023 PDS BIOTECHNOLOGY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer

Exhibit 99.1 PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer ● First study of patients with metastatic prostate cancer to evaluate standard-of-care chemotherapy (docetaxel) combined with an antibody drug conjugate (PDS0301). ● Decrease in prostate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2023 PDS BIOTECHNOLOGY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA

Exhibit 99.1 PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) • Interim VERSATILE-002 data for the first-line treatment of recurrent or metastatic head and neck cancer patients who were immune checkpoint inhibitor (ICI) naïve; published 24-month survival

Developing Transformational Immunotherapies for Cancer NASDAQ: PDSB October 2023 PDS0101 to enter Phase 3 registrational trial in 2023 to treat recurrent or metastatic, HPV16-positive head and neck squamous cell cancer (HNSCC) Fast Track Designation

Exhibit 99.1 Developing Transformational Immunotherapies for Cancer NASDAQ: PDSB October 2023 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation

PDS0101 in HPV16+ Head and Neck Cancer KOL Roundtable NASDAQ: PDSB October 3, 2023 Disclaimer PDS Biotech is the sponsor of this roundtable Each panelist is speaking on behalf of PDS Biotech under the terms of a consulting agreement Information prese

Exhibit 99.1 PDS0101 in HPV16+ Head and Neck Cancer KOL Roundtable NASDAQ: PDSB October 3, 2023 Forward Looking Statements Versamune® and Infectimune® are registered trademarks of PDS Biotechnology Corporation.KEYTRUDA® is a registered trademark of Merck Sharp and Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Certain information in this presentation may include forward-looking sta

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 PDS BIOTECHNOLOGY C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)

Exhibit 99.1 PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA) ● Study evaluated levels of circulating cell-free HPV DNA (cfDNA) in patients with locally advanced cervical cancer in the IMMUNOCERV Phase 2 clinical trial and patients receiving standard of care (SOC) treatment ● Patients treated with PDS0101 had greater

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 PDS BIOTECHNOLOGY C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies

Exhibit 99.1 PDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies ● PDS0202 (Infectimune® + COBRA influenza antigens) vaccination also prevented illness/weight loss ● Vaccine protected against replication of the virus in the lungs of ferrets after challenge with the H1N1 virus ● Data from Cleveland Clinic’s Ted Ross Lab presented at the 9

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Developing Transformational Immunotherapies for Cancer NASDAQ: PDSB September 2023 PDS0101 to enter Phase 3 registrational trial in 2023 to treat recurrent or metastatic, HPV16-positive head and neck squamous cell cancer (HNSCC) Fast Track Designatio

Exhibit 99.1 Developing Transformational Immunotherapies for Cancer NASDAQ: PDSB September 2023 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 PDS BIOTECHNOLOGY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS0202 Universal Influenza Preclinical Ferret Data to be Presented in Oral Lecture at 9th ESWI Conference

Exhibit 99.1 PDS0202 Universal Influenza Preclinical Ferret Data to be Presented in Oral Lecture at 9th ESWI Conference PRINCETON, N.J., September 6, 2023 (GLOBE NEWSWIRE) - PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Developing Transformational Immunotherapies for Cancer NASDAQ: PDSB August 2023 PDS0101 to enter Phase 3 registrational trial in 2023 to treat recurrent or metastatic, HPV16-positive head and neck squamous cell cancer (HNSCC) Fast Track Designation P

Exhibit 99.1 Developing Transformational Immunotherapies for Cancer NASDAQ: PDSB August 2023 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation

PDS Biotech Announces Data from IMMUNOCERV Phase 2 Trial Investigating PDS0101 and Chemoradiotherapy in Cervical Cancer to be Featured in Oral Presentation at the ASTRO 2023 Annual Meeting Study evaluates the effect of combining PDS0101 with standard

Exhibit 99.1 PDS Biotech Announces Data from IMMUNOCERV Phase 2 Trial Investigating PDS0101 and Chemoradiotherapy in Cervical Cancer to be Featured in Oral Presentation at the ASTRO 2023 Annual Meeting Study evaluates the effect of combining PDS0101 with standard of care on levels of circulating HPV viral DNA in cervical cancer patients and impact on disease status and clearance Princeton, N.J., A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2023 PDS BIOTECHNOLOGY C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37568 PDS Biotechnol

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 PDS BIOTECHNOLOGY C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business Update

Exhibit 99.1 PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business Update ● Successful submission of final clinical protocol and supporting CMC information to FDA to initiate Phase 3 VERSATILE-003 trial in the fourth quarter 2023 ● Biomarker data from VERSATILE-002 to be presented at ESMO 2023 ● Company to host conference call and webcast today at 8:00 AM EDT PRINCETON, N

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial

Exhibit 99.1 PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial VERSATILE-003 will evaluate PDS0101 in combination with KEYTRUDA® in recurrent or metastatic HPV16-positive head and neck cancer PDS Biotech anticipates initiating the VERSATILE-003 trial in the fourth quarter of 2023 Princeton, NJ, August 14, 2023 - PDS Biotechnology Corporation (Nasdaq: PDSB)

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech to Present Updated Immune Response Data from Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients at ESMO Congress 2023 Data from ongoing VERSATILE-002 trial to highlight HPV16-specific T cell responses in

Exhibit 99.1 PDS Biotech to Present Updated Immune Response Data from Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients at ESMO Congress 2023 Data from ongoing VERSATILE-002 trial to highlight HPV16-specific T cell responses in subjects receiving PDS0101 and KEYTRUDA® for recurrent or metastatic HPV16-positive head and neck cancer Florham Park, NJ, July 25, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2023 PDS BIOTECHNOLOGY COR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Announces Acceptance of Abstract on Combination of PDS0301 with Docetaxel in Metastatic Prostate Cancer for Oral Presentation by the National Cancer Institute at Cytokines 2023

Exhibit 99.1 PDS Biotech Announces Acceptance of Abstract on Combination of PDS0301 with Docetaxel in Metastatic Prostate Cancer for Oral Presentation by the National Cancer Institute at Cytokines 2023 First clinical study of immunocytokine with docetaxel in prostate cancer patients Florham Park, NJ, July 17, 2023 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy compa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 14, 2023 Date of Report (Date of earliest event reported) PDS Biotechnology Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 14, 2023 Date of Report (Date of earliest event reported) PDS Biotechnology Corporation (Exact name of registrant as specified in its charter) Delaware 001-37568 26-4231384 (State or other jurisdiction of incorporation) (Commiss

THIRD AMENDED AND RESTATED PDS BIOTECHNOLOGY CORPORATION 2014 EQUITY INCENTIVE PLAN Adopted by the Board of Directors on May 19, 2023 THIRD AMENDED AND RESTATED PDS BIOTECHNOLOGY CORPORATION 2014 EQUITY INCENTIVE PLAN

Exhibit 10.1 THIRD AMENDED AND RESTATED PDS BIOTECHNOLOGY CORPORATION 2014 EQUITY INCENTIVE PLAN Adopted by the Board of Directors on May 19, 2023 THIRD AMENDED AND RESTATED PDS BIOTECHNOLOGY CORPORATION 2014 EQUITY INCENTIVE PLAN Section 1. Purpose of the Plan. The purpose of the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (formerly known as the Second Amen

PDS Biotech Strengthens Intellectual Property Portfolio Governing A Combination of Versamune® and PDS0301

Exhibit 99.1 PDS Biotech Strengthens Intellectual Property Portfolio Governing A Combination of Versamune® and PDS0301 • Composition of matter and use patent for Versamune® in combination with PDS0301 allowed in Canada • PDS Biotech’s proprietary combination of Versamune® based PDS0101 and PDS0301 with an immune checkpoint inhibitor resulted in 21 months median overall survival in advanced HPV-pos

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2023 PDS BIOTECHNOLOGY COR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Developing Transformational Immunotherapies for Cancer NASDAQ: PDSB June 2023 PDS0101 to enter Phase 3 registrational trial in 2023 to treat recurrent or metastatic, HPV-positive head and neck squamous cell cancer (HNSCC) Fast Track Designation PDS01

Exhibit 99.1 Developing Transformational Immunotherapies for Cancer NASDAQ: PDSB June 2023 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 PDS BIOTECHNOLOGY COR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the VERSATILE-002 Trial Evaluating PDS0101 and KEYTRUDA® in Head and Neck Cancer

Exhibit 99.1 PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the VERSATILE-002 Trial Evaluating PDS0101 and KEYTRUDA® in Head and Neck Cancer • 14 patients in the immune checkpoint inhibitor naïve arm of VERSATILE-002 have experienced either a complete response or partial response on two consecutive scans, thus constituting a confirmed objective response • Efficacy and

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

FORM ARS

PDS BIOTECHNOLOGY CORPORATION 2022 Annual Report 8 NITED STATES SEC8 RITIES AND E; CHAN* E COMMISSION : ashington D C 20 FORM 10-K (Mark One) ☒ ANN8 AL REPORT 8 NDER SECTION 1 OR 1 d OF THE SEC8 RITIES E; CHAN* E ACT OF 1 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT 8 NDER SECTION 1 OR 1 d OF THE SEC8 RITIES E; CHAN* E ACT OF 1 For the transition period from to Commission file number 001-37568 PDS Biotechnolog\ Corporation (Exact name of registrant as specified in its charter) DelaZ are 2 - 2 1 (State or other urisdiction of incorporation or organi ation) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rul

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi

Developing Transformational Immunotherapies for Cancer NASDAQ: PDSB May 2023 PDS0101 to enter Phase 3 registrational trial in 2023 to treat recurrent or metastatic, HPV-positive head and neck squamous cell cancer (HNSCC) Fast Track Designation PDS010

Exhibit 99.1 Developing Transformational Immunotherapies for Cancer NASDAQ: PDSB May 2023 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 PDS BIOTECHNOLOGY CORP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 PDS BIOTECHNOLOGY CORP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients

Exhibit 99.1 PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients • Interim data being presented at ASCO 2023 Annual Meeting • Demonstrated median progression-free survival (PFS) of 10.4 months • Demonstrated 12-month overall survival (OS) rate of 87.1% • A disease control rate (di

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 PDS BIOTECHNOLOGY CORP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Developing Transformational Immunotherapies for Cancer NASDAQ: PDSB May 2023 PDS0101 to enter Phase 3 registrational trial in 2023 to treat recurrent or metastatic, HPV-positive head and neck squamous cell cancer (HNSCC) Fast Track Designation PDS010

Exhibit 99.1 Developing Transformational Immunotherapies for Cancer NASDAQ: PDSB May 2023 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (th

PDS Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of VERSATILE-002 Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer

Exhibit 99.1 PDS Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of VERSATILE-002 Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer Company plans to initiate VERSATILE-003 Phase 3 clinical trial in late 2023 FLORHAM PARK, N.J., May 18, 2023 (GLOBE NEWSWIRE) - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Precision Designed Science For Immunotherapy INVESTOR PRESENTATION NASDAQ: PDSB | May 2023 3 About PDS Biotechnology Company Overview T cell activating platforms and antibody conjugated immuno-cytokine platform to develop safer, more effective and lo

Exhibit 99.1 Precision Designed Science For Immunotherapy INVESTOR PRESENTATION NASDAQ: PDSB | May 2023 2 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

PDS Biotech Provides Business Update and Reports First Quarter 2023 Financial Results

Exhibit 99.1 PDS Biotech Provides Business Update and Reports First Quarter 2023 Financial Results Updated data from VERSATILE-002 Phase 2 trial to be presented at ASCO 2023 Company to host conference call and webcast today, May 15, 2023, at 8:00 AM ET FLORHAM PARK, N.J., May 15, 2023 (GLOBE NEWSWIRE) - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage company developing a growing pip

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37568 PDS Biotechno